Eton Pharmaceuticals, Inc.

About Eton Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. We currently have eight commercial rare disease products: INCRELEX , ALKINDI SPRINKLE , KHINDIVI TM , GALZIN , PKU GOLIKE , Carglumic Acid, Betaine Anhydrous, and Nitisinone. We have five additional product candidates in late-stage development: ET-600, Amglidia , ET-700, ET-800 and ZENEO hydrocortisone autoinjector. INCRELEX This biologic product was approved by the FDA in August 2005 as a treatment for children who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). The product is approved in 40 territories, including the United States and the European Union. We acquired and launched the product in December 2024. ALKINDI SPRINKLE This product was approved by the FDA in September 2020 as a replacement therapy for Adrenocortical Insufficiency ( AI ) in children under 17 years of age. The product is the first and only FDA-approved granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with AI. We acquired U.S. marketing rights to the product in March 2020 and launched ALKINDI SPRINKLE in December 2020 with a sales force targeting pediatric endocrinologists. We believe there are approximately 10,000 children currently suffering from AI in the United States. ALKINDI SPRINKLE is protected by three issued patents that extend to 2032, 2033, and 2034.